Adair Newhall


Adair is a principal at Greenspring Associates and is responsible for sourcing and due diligence efforts on fund, direct and secondary opportunities. He leads the firm’s healthcare and portfolio impact practices. Adair currently serves on the Bright Health & Crown Labs boards and sits as an observer on the Aetion and Paladina Health boards. He also advises five different Venture Advisory Boards for venture capital firms and five passive direct healthcare investments (Imago Biosciences, Kallyope, NGM Bio, Phathom Pharma, PowerVision, ScoutBio, & Tenaya Therapeutics).  Adair previously served as a principal at Domain Associates, a leading healthcare focused venture capital firm and a Greenspring Associates fund manager. At Domain Associates, he held board observer positions with several portfolio companies including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals, Otonomy, and Xagenic. Prior to joining Domain Associates in August 2009, Adair worked in the business development group at Esprit Pharma, where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan (NYSE: AGN) for $370 million. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $514 million. He received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania.

Adair is a Kauffman Fellow, a member of the Baltimore/Washington Chapter of YPO, and a co-founder of the UVa Venture Summit.

Philanthropically, he is passionate about his activities with We.Org, Living Classrooms Foundation, and Darden Business School Foundation Board of Trustees.